Breaking News, Collaborations & Alliances, Trials & Filings

Trials & Filings in Brief: Jan. 7, 2014

Alitair, Celgene, Erytech, Galena, Neurocrine, Orexigen, Shield, TeaRx

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Phase II Erytech to begin pancreatic cancer study . . . read more Galena enrolls first ovarian cancer patient . . . read more Neurocrine Biosciences posts positive results in tardive dyskinesia . . . read more TeaRx begins anticoagulant trial . . . read more Phase III Positive results for Shield’s IDA treatment in IBD . . . read more Approvals Celgene’s Abraxane approved in EU for pancreatic cancer . . . read more Filings Alitair gets orphan status for bronchiectasis treatment ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters